PATENT CLAIM ANALYSIS

Application Number: 15758045
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "229800"]

Abstract:
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus: The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a therapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.

Claim (Index 23):
A method for treating a disease in a patient chosen from:\n (a) cancer (b) diabetes (c) autoimmune disease (d) age onset proteotoxic disease (e) mood disorder (f) acne vulgaris (g) solid organ transplant rejection (h) graft vs. host disease (i) cardiac hypertrophy (j) viral infection and (k) parasitic infection; the method comprising administering to the patient a therapeutically effective amount of a compound according to  claim 1 .

Metadata:
- Claim Count in Document: 46.0
- Percentile: 90.0
- Lexical Diversity: 1.42105
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15758038', '15124891', '15750388', '12041860', '11862690']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7875218570970965
- 35 USC 102 Novelty (BERT): 0.5538698444190993
- Combined Prediction Score: 0.7641566558292968
- Mean Citation Score: 340.52525
- Max Citation Score: 418.73618
- Similarity Product: 384.46983994318254

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test